Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) had its price target lowered by equities researchers at Needham & Company LLC from $38.00 to $10.00 in a report released on Monday,Benzinga reports.
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Canaccord Genuity Group in a note issued to investors on Monday, MarketBeat reports.
Lipella Pharmaceuticals LIPO stock moved upwards by 49.5% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.5 million. IN8bio INAB shares increased by ...